Graft-versus-host disease (GvHD) of the skin is a severe allo-immune reaction and complication following allogeneic stem cell transplantation. Over the past years, intensive pre-clinical research has led to an improved understanding of the pathophysiology of acute and to a lesser extend chronic GvHD. This has translated into the approval of several new agents for the treatment of both forms of GvHD. This review summarizes the most recent advances in underlying pathomechanisms, clinical trials and newly approved agents for GvHD, with a special focus on skin involvement.
| Identifer | oai:union.ndltd.org:DRESDEN/oai:qucosa:de:qucosa:91191 |
| Date | 30 May 2024 |
| Creators | Link-Rachner, Cornelia S., Sockel, Katja, Schuetz, Catharina |
| Publisher | Frontiers Media |
| Source Sets | Hochschulschriftenserver (HSSS) der SLUB Dresden |
| Language | English |
| Detected Language | English |
| Type | info:eu-repo/semantics/publishedVersion, doc-type:article, info:eu-repo/semantics/article, doc-type:Text |
| Rights | info:eu-repo/semantics/openAccess |
| Relation | 1664-3224, 838494, 10.3389/fimmu.2022.838494 |
Page generated in 0.0018 seconds